Why Pfizer Will Profit From Merck's Rival Pneumococcal Vaccine

Why Pfizer Will Profit From Merck's Rival Pneumococcal Vaccine

Submitted by admin on October 9, 2021 - 11:05pm
Source: 
Motley Fool
News Tags: 
Pfizer
Merck
vaccines
pneumococcal disease
Headline: 
Why Pfizer Will Profit From Merck's Rival Pneumococcal Vaccine
snippet: 
  • Pfizer and Merck recently settled a lawsuit related to Pfizer's patents for pneumococcal vaccines.
  • Pfizer will receive 7.25% royalties on Merck's vaccine through 2026 and 2.5% from then through 2035.
  • The settlement makes sense, but Pfizer's vaccine is likely to be the bigger long-term winner.

Do Not Allow Advertisers to Use My Personal information